Patents by Inventor Hugh Wiltshire

Hugh Wiltshire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20230346796
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: July 10, 2023
    Publication date: November 2, 2023
    Applicant: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20200316088
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in Ft dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: June 18, 2020
    Publication date: October 8, 2020
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Dosing regimen for sedation with CNS 7056 (remimazolam)
    Patent number: 10722522
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 28, 2020
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20200171046
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: June 28, 2019
    Publication date: June 4, 2020
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 10342800
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: July 9, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20190111062
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: December 7, 2018
    Publication date: April 18, 2019
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 10195210
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: February 5, 2019
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20180318316
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 8, 2018
    Applicant: PAION UK LIMITED
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Dosing regimen for sedation with CNS 7056 (remimazolam)
    Patent number: 10052334
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: August 21, 2018
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20180042939
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: October 24, 2017
    Publication date: February 15, 2018
    Applicant: Paion UK Limited
    Inventors: Karin WILHELM-OGUNBIYI, Keith BORKETT, Gary Stuart TILBROOK, Hugh WILTSHIRE
  • Dosing regimen for sedation with CNS 7056 (remimazolam)
    Patent number: 9827251
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: November 28, 2017
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 9737547
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: August 22, 2017
    Assignee: PAION UK LIMITED
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20170112852
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: January 6, 2017
    Publication date: April 27, 2017
    Inventors: Karin WILHELM-OGUNBIYI, Keith BORKETT, Gary Stuart TILBROOK, Hugh WILTSHIRE
  • Dosing regimen for sedation with CNS 7056 (Remimazolam)
    Patent number: 9561236
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Grant
    Filed: November 7, 2011
    Date of Patent: February 7, 2017
    Assignee: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire
  • DOSING REGIMEN FOR SEDATION WITH CNS 7056 (REMIMAZOLAM)
    Publication number: 20140080815
    Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 10 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.
    Type: Application
    Filed: November 7, 2011
    Publication date: March 20, 2014
    Applicant: PAION UK LTD.
    Inventors: Karin Wilhelm-Ogunbiyi, Keith Borkett, Gary Stuart Tilbrook, Hugh Wiltshire